Braasch Biotech LLC announces its lead vaccine for Obesity, Growth Hormone Deficiencies may have beneficial use for numerous IGF-1 responsive disorders such as diabetes, heart disease and Rett Syndrome based on initial preclinical testing in a mouse model.
A new vaccine technology that stimulates the body to release more of its own Growth Hormone ("GH") and Insulin Growth Factor 1 ("IGF-1") is expected to open a new world of treatment options for growth hormone deficiencies, obesity, specific types of diabetes as well as for a potentially long list of IGF-1 responsive neurological disorders. Braasch Biotech LLC announced today that they have successfully created a vaccine technology specifically designed to generate a high level of antibodies against somatostatin, the inhibiting hormone that controls the release of Growth Hormone. The vaccine's mode of action is to generate highly specific antibodies which attenuate but do not entirely eliminate the mostly inhibitory actions of somatostatin, which helps the body to continue to release more of its own GH and IGF-1. Braasch's innovative approach allows the body to do this on its own without having to use "drugs" and thereby presents a new treatment option for human medicine.
Researchers have been working unsuccessfully for over two decades to make early versions of somatostatin vaccines sufficiently effective to be commercialized. Building on the pioneering approaches originally invented and patented by Russian scientists, Braasch and its science collaboration team created a novel second-generation vaccine technology which dramatically improves the effectiveness of the first-generation prototype vaccine. Besides refining the vaccine and its formulation, Braasch, in conjunction with the University of Iowa's Center for Biocatalysis and Bioprocessing, has developed scalable manufacture and isolation processes to provide uniform vaccine for laboratory testing. The new vaccine is designed for once-per-month treatment versus treatment regiments using Growth Hormone Drugs which typically require daily injection.